Alnylam Pharmaceuticals Inc To Discuss FDA Approval of AMVUTTRA for ATTR-CM Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Ritu Baral - TD Cowen - Analyst : Hi, guys. Congratulations on the approval. A quick question on some specific language in the label. Tolga, what value do you see the urgent heart failure visit reduction language presenting to payers, especially as you contemplate frontline coverage for AMVUTTRA in this indication? Thanks.

Question: Jessica Fye - JPMorgan Chase & Co - Analyst : Hey, guys. Good evening. Thanks for taking my questions. So in the past, you've talked about 5,000 to 10,000 cardiomyopathy patients initiating treatment in the US each year at an increasing rate. I'm curious, if we look out, say, five years from now, where do you think that 5,000 to 10,000 per year initiating treatment is going to go?

Question: Tazeen Ahmad - Bank of America - Analyst : Hi, good evening. Thanks for taking my question. This is probably for Tolga. Can you give us a sense, you've talked a lot about your focus on frontline new patients. But as the launch is going to progress, how should we be thinking about switch patients or add-on patients? I guess in the label, there doesn't seem to be reference about how to use it in combination with stabilizers. And does that impact at all your view of the opportunity beyond frontline? Thanks.

Question: Paul Matteis - Stifel Financial Corp - Analyst : Hey, thanks so much and congratulations. I wanted to ask a little bit more about your thought process behind pricing. When you've engaged with Medicare plans, to what degree do you think that the Part B book of business is truly looked at in a vacuum? And I guess, is your thinking that the price of AMVUTTRA shouldn't really be comped or I guess, won't be comped by insurers to the price of tafamidis and acoramidis? And I guess that is sort of what I'm ultimately wondering here as to what gave you the confidence to price and maintain price at a significant premium. Thanks so much.

Question: Konstantinos Biliouris - BMO Capital Markets - Analyst : Hello, everyone. Congrats on the approval. Thanks for taking our questions. One question from us on recent real-world evidence data from tafamidis, which saw that the discontinuation rate is actually very high, 30% to 40% between 12 and 24 months. We would be interested in hearing your thoughts around what can you do to secure that those patients who are discontinuing tafamidis, they prefer to come to silencers versus another stabilizer. And also, although Tolga mentioned some of those, any measures you are taking to avoid such high discontinuation break with AMVUTTRA? Thank you and congrats again.

Question: Maury Raycroft - Jefferies Group LLC - Analyst : Hi. I'll add my congrats and thanks for taking my question. I was just going to ask about the -- for the patient assistance program and initial free dose if there's coverage issues. What are your expectations for this at the start of launch? And how could this evolve over time? Maybe just provide more perspective on that. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 20, 2025 / 10:00PM, ALNY.OQ - Alnylam Pharmaceuticals Inc To Discuss FDA Approval of AMVUTTRA for ATTR-CM

Question: David Lebowitz - Citi - Analyst : Thank you very much for taking my question and congratulations on the approval. On pricing, while you're maintaining the current list price and you're going to be making use of rebates and whatnot to lower the net price over time. I'm curious to start with what type of differential might there be between the cardiomyopathy and polyneuropathy at the get-go relative to these rebates and aspects on net pricing? And will that actually differentiate over time with polyneuropathy maintaining a more premium approach and then cardiomyopathy potentially having more of an impact?

Question: Gena Wang - Barclays - Analyst : Thank you. Also congrats on the early approval and with a strong label. So regarding the net price, you mentioned that it will be decreased over time. And how much net price impact to your 2025 revenue guidance, especially given like it's a $1.22 billion revenue in 2024 in polyneuropathy. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 20, 2025 / 10:00PM, ALNY.OQ - Alnylam Pharmaceuticals Inc To Discuss FDA Approval of AMVUTTRA for ATTR-CM

Question: Gena Wang - Barclays - Analyst : Thank you.

Question: Gary Nachman - Raymond James Financial Inc - Analyst : Thanks and my congrats as well on the approval. So understanding this is more of a second half impact on the launch, what type of metrics will you provide to give us a sense of how the CM launch is going in terms of payer access, patients treated, physician prescribing or anything else that you could talk to give us a sense of the launch? Thanks.

Question: Luca Issi - RBC Capital Markets - Analyst : Great. Thanks so much for taking the question. Congrats on the approval. I know it's a long journey, so congrats. Maybe Tolga, a quick one for you. It feels to me that this drug is going to do really well at top academic centers, especially given the favorable

Question: Ellie Merle - UBS - Analyst : Hey, guys. Thanks so much for taking the question. Just in terms of combination use, what the payers said about this in your initial conversation. And then in terms of the at-home infusion option that you mentioned, what's the (inaudible) in polyneuropathy? And how do you expect that to compare in cardiomyopathy? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 20, 2025 / 10:00PM, ALNY.OQ - Alnylam Pharmaceuticals Inc To Discuss FDA Approval of AMVUTTRA for ATTR-CM